American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline

Abstract

The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline. A total of 1,073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.This guideline was developed through a collaboration between the American Cancer Society and the American Society of Clinical Oncology and has been published jointly by invitation and consent in both CA: A Cancer Journal for Clinicians and Journal of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Cancer Society or the American Society of Clinical Oncology.

Long noncoding RNA EZR‑AS1 promotes tumor growth and metastasis by modulating Wnt/β‑catenin pathway in breast cancer

“…Breast cancer (BC) is one of the most common and malignant cancers that affects among women around the world (1). However, the underlying mechanisms responsible for BC development and progression remain unknown.…”

“…Breast cancer (BC) is one of the most common and malignant cancers affecting women worldwide (1). The incidence of BC is increasing rapidly, especially in China (2).…”

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

“…In addition, the period immediately after treatment has been identified as a time of increased psychosocial distress among survivors (Montazeri et al, 2008;Paraskevi, 2012). Immediate access to supportive care is therefore crucial to address psychosocial issues and improve QoL outcomes both in the short and long term in these patients (Runowicz et al, 2016).…”

Síndrome de cáncer hereditario de mama y ovario: aplicación clínica

“…La realización de una mastectomía profiláctica bilateral en casos de alto riesgo, como las pacientes con cánceres hereditarios es una opción recomendada por la "Guía de manejo de la Sociedad Americana de Oncología Clínica para la supervivencia de los pacientes con cáncer" (59). Basados en los riesgos explicados usted debe tomar la decisión con ayuda de su médico (54).…”